Purple Biotech (PPBT) Other Accumulated Expenses (2014 - 2026)

Purple Biotech (PPBT) has reported Other Accumulated Expenses for 13 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 24.37% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 24.37% YoY), while the FY2025 annual figure was $1.4 million, up 14.42% from the prior year.
• Other Accumulated Expenses improved to $1.7 million in Q1 2026 per PPBT's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.3 million in Q1 2022 and bottomed at $1.2 million in Q2 2025.
• Historically, Other Accumulated Expenses has averaged $2.6 million across 5 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 223.72% — and 2024, when it tumbled 65.35%.
• Purple Biotech's Other Accumulated Expenses stood at $4.7 million in 2022, then slipped by 26.82% to $3.5 million in 2023, then sank by 65.35% to $1.2 million in 2024, then rose by 14.42% to $1.4 million in 2025, then climbed by 21.56% to $1.7 million in 2026.
• Business Quant data shows PPBT's Other Accumulated Expenses at $1.7 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.